Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis DOI Creative Commons
Petros Pousinis, Olga Begou, Marina Boziki

и другие.

Metabolites, Год журнала: 2024, Номер 14(10), С. 545 - 545

Опубликована: Окт. 13, 2024

Multiple sclerosis (MS) is a neurodegenerative and inflammatory disease of the central nervous system (CNS) that leads to loss myelin. There are three main types MS: relapsing-remitting MS (RRMS) primary secondary progressive (PPMS, SPMS). The differentiation in pathogenesis these two latter courses still unclear. underlying mechanisms yet be elucidated, treatment relies on immune-modifying agents. Recently, lipidomics metabolomics studies using human biofluids, mainly plasma cerebrospinal fluid (CSF), have suggested an important role lipids metabolites pathophysiology MS. In this review, results from analyses performed biological samples patients MS-like animal models presented analyzed. Based collected findings, biochemical pathways cohorts involved were investigated potential they discussed. Limitations challenges approaches while concluding may provide more holistic approach biomarkers for early diagnosis disease.

Язык: Английский

Effect of Treatment on Steroidome in Women with Multiple Sclerosis DOI Open Access
Martin Hill,

Radmila Kancheva,

Marta Velíková

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 1835 - 1835

Опубликована: Фев. 20, 2025

Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system. The manifestation MS related to steroid changes during menstrual cycle and pregnancy. As data focusing on effect anti-MS drug treatment steroidome are scarce, we evaluated steroidomic (79 steroids) in 61 female patients reproductive age 39 (29, 47) years (median with quartiles) after drugs GC-MS/MS platform immunoassays (cortisol estradiol). were assessed using levels molar ratios (SMRs) that may reflect activities steroidogenic enzymes (SMRs). A repeated measures ANOVA, followed by multiple comparisons OPLS models, used for statistical analyses. decreased follicular phase. Anti-CD20 monoclonal antibodies (mAb), such as ofatumumab ocrelizumab; inhibitors sphingosine-1-phosphate receptor (S1PRI); IFNβ-1a circulating 17-hydroxy-pregnanes shifted CYP17A1 functioning from hydroxylase- toward lyase step. Decreased conjugated/unconjugated found drugs, especially glatiramer acetate anti-CD20 mAb. In luteal phase, IFN-β1a increased steroidogenesis; both ocrelizumab AKR1D1, S1PRI SRD5A functioning. mAb reduced catalyzing synthesis immunomodulatory 7α/β 16α-hydroxy-androgens, which affect severity MS. above findings be important concerning alterations bioactive steroids, cortisol; active androgens estrogens; neuroactive, neuroprotective, steroids terms optimization treatment.

Язык: Английский

Процитировано

0

Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis DOI Creative Commons
Petros Pousinis, Olga Begou, Marina Boziki

и другие.

Metabolites, Год журнала: 2024, Номер 14(10), С. 545 - 545

Опубликована: Окт. 13, 2024

Multiple sclerosis (MS) is a neurodegenerative and inflammatory disease of the central nervous system (CNS) that leads to loss myelin. There are three main types MS: relapsing-remitting MS (RRMS) primary secondary progressive (PPMS, SPMS). The differentiation in pathogenesis these two latter courses still unclear. underlying mechanisms yet be elucidated, treatment relies on immune-modifying agents. Recently, lipidomics metabolomics studies using human biofluids, mainly plasma cerebrospinal fluid (CSF), have suggested an important role lipids metabolites pathophysiology MS. In this review, results from analyses performed biological samples patients MS-like animal models presented analyzed. Based collected findings, biochemical pathways cohorts involved were investigated potential they discussed. Limitations challenges approaches while concluding may provide more holistic approach biomarkers for early diagnosis disease.

Язык: Английский

Процитировано

1